https://ced-studienzentrum.berlin/abtect-1-studie-zu-colitis-ulcerosa/ 2026-01-19T11:30:38+00:00 https://ced-studienzentrum.berlin/morbus-crohn-graviti-studie-guselkumab-als-subkutane-therapie/ 2026-01-19T11:40:35+00:00 https://ced-studienzentrum.berlin/morbus-crohn-fortify-studie-risankizumab/ 2026-01-19T11:41:20+00:00 https://ced-studienzentrum.berlin/morbus-crohn-duet-cd-studie-kombination-guselkumab-und-golimumab/ 2026-01-19T11:41:57+00:00 https://ced-studienzentrum.berlin/colitis-ulcerosa-duet-uc-studie-kombination-guselkumab-und-golimumab/ 2026-01-19T11:42:36+00:00 https://ced-studienzentrum.berlin/colitis-ulcerosa-command-studie-risankizumab/ 2026-01-19T11:42:49+00:00 https://ced-studienzentrum.berlin/colitis-ulcerosa-abtect-maintenance-studie/ 2026-01-19T11:43:02+00:00 https://ced-studienzentrum.berlin/morbus-crohn-sar441566-studie-3/ 2026-01-19T11:43:35+00:00 https://ced-studienzentrum.berlin/colitis-ulcerosa-miracle-studie-studienpartner/ 2026-01-19T11:43:48+00:00 https://ced-studienzentrum.berlin/morbus-crohn-sar441566-studie-2/ 2026-01-19T11:44:04+00:00 https://ced-studienzentrum.berlin/colitis-ulcerosa-miracle-studie/ 2026-01-19T11:44:20+00:00 https://ced-studienzentrum.berlin/morbus-crohn-sar441566-studie/ 2026-01-19T11:44:35+00:00 https://ced-studienzentrum.berlin/colitis-ulcerosa-abtect-erhaltungstherapie/ 2026-01-26T13:41:26+00:00 https://ced-studienzentrum.berlin/colitis-ulcerosa-studie-zur-wirksamkeit-und-sicherheit-von-risankizumab/ 2026-01-26T13:42:48+00:00 https://ced-studienzentrum.berlin/colitis-ulcerosa-kombinationsstudie-mit-guselkumab-und-golimumab-duet-uc/ 2026-01-26T13:43:45+00:00 https://ced-studienzentrum.berlin/morbus-crohn-kombinationsstudie-mit-guselkumab-und-golimumab-bei-morbus-crohn-duet-cd/ 2026-01-26T13:45:05+00:00 https://ced-studienzentrum.berlin/morbus-crohn-studie-zu-subkutanem-guselkumab-graviti/ 2026-01-26T13:45:54+00:00 https://ced-studienzentrum.berlin/morbus-crohn-studie-zur-wirksamkeit-und-sicherheit-von-risankizumab-fortify/ 2026-01-26T13:47:07+00:00 https://ced-studienzentrum.berlin/en/crohns-disease-study-on-subcutaneous-guselkumab-graviti/ 2026-02-03T10:01:12+00:00 https://ced-studienzentrum.berlin/en/crohns-disease-study-on-the-efficacy-and-safety-of-risankizumab-fortify/ 2026-02-03T10:01:12+00:00 https://ced-studienzentrum.berlin/en/crohns-disease-combination-study-with-guselkumab-and-golimumab-in-crohns-disease-duet-cd/ 2026-02-03T10:01:14+00:00 https://ced-studienzentrum.berlin/en/ulcerative-colitis-combination-study-with-guselkumab-and-golimumab-duet-uc/ 2026-02-03T10:01:21+00:00 https://ced-studienzentrum.berlin/en/ulcerative-colitis-abtect-maintenance-therapy/ 2026-02-03T10:01:26+00:00 https://ced-studienzentrum.berlin/en/crohns-disease-sar441566-study/ 2026-02-03T10:03:02+00:00 https://ced-studienzentrum.berlin/en/ulcerative-colitis-miracle-study/ 2026-02-03T10:03:02+00:00 https://ced-studienzentrum.berlin/en/ulcerative-colitis-duet-uc-study-combination-of-guselkumab-and-golimumab/ 2026-02-03T10:03:06+00:00 https://ced-studienzentrum.berlin/en/crohns-disease-fortify-study-risankizumab/ 2026-02-03T10:03:06+00:00 https://ced-studienzentrum.berlin/en/crohns-disease-graviti-study-guselkumab-as-subcutaneous-therapy/ 2026-02-03T10:03:06+00:00 https://ced-studienzentrum.berlin/en/crohns-disease-duet-cd-study-combination-of-guselkumab-and-golimumab/ 2026-02-03T10:03:06+00:00 https://ced-studienzentrum.berlin/en/ulcerative-colitis-command-study-risankizumab/ 2026-02-03T10:03:06+00:00 https://ced-studienzentrum.berlin/en/ulcerative-colitis-miracle-study-study-partners/ 2026-02-03T10:03:07+00:00 https://ced-studienzentrum.berlin/en/abtect-1-study-on-ulcerative-colitis/ 2026-02-03T10:03:07+00:00 https://ced-studienzentrum.berlin/en/abtect-1-study-on-ulcerative-colitis-study-partners/ 2026-02-03T10:03:07+00:00 https://ced-studienzentrum.berlin/en/crohns-disease-sar441566-study-study-partner/ 2026-02-03T10:03:07+00:00 https://ced-studienzentrum.berlin/en/ulcerative-colitis-abtect-maintenance-study/ 2026-02-03T10:03:07+00:00 https://ced-studienzentrum.berlin/en/ulcerative-colitis-study-on-the-efficacy-and-safety-of-risankizumab/ 2026-02-03T10:03:09+00:00